[1] 刘泽洲,苏可,杨定平,等.IgA肾病伴高血压患者临床病理改变特征及预后分析[J].中华肾脏病杂志,2019,35(9):648-654. [2] NAKA S,WATO K,MISAKI T,et al.Streptococcus mutans induces IgA nephropathy-like glomerulonephritis in rats with severe dental caries[J].Sci Rep,2021,11(1):5784. [3] 弓思文. 局灶节段性肾小球硬化在IgA肾病中的发展机制[J].临床与病理杂志,2019,39(2):419-423. [4] 彭思琪,卢文,江肖,等.742例原发性IgA肾病患者的临床病理特征及其预后分析[J].中华肾脏病杂志,2021,37(2):87-94. [5] PENG W,TANG Y,TAN L,et al.Crescents and global glomerulosclerosis in Chinese IgA nephropathy patients:A five-year follow-up[J].Kidney Blood Press Res,2019,44(1):103-112. [6] 郑法雷. 肾脏病临床与进展[M].北京:人民军医出版社,2005. [7] TAYLOR S,WHITFIELD M,BARRATT J,et al.The metalloproteinase ADAMTS5 is expressed by interstitial inflammatory cells in IgA nephropathy and is proteolytically active on the kidney matrix[J].J Immunol,2020,205(8):2243-2254. [8] 王永超,刘新宇.单核细胞/高密度脂蛋白胆固醇比值与2型糖尿病肾脏疾病的相关性分析[J].中国现代医学杂志,2020,30(23):77-83. [9] MARKOWITZ G.Glomerular disease:Updated Oxford classification of IgA nephropathy:a new MEST-C score[J].Nat Rev Nephrol,2017,13(7):385-386. [10] KATAFUCHI R,KIYOSHI Y,OH Y,et al.Glomerular score as a prognosticator in IgA nephropathy:Its usefulness and limitation[J].Clin Nephrol,1998,49(1):1-8. [11] 陈梅,廖蕴华.原发性IgA肾病流行病学进展[J].医学研究杂志,2007,36(11):24-26. [12] MOROOKA M,KAWAGUCHI T,MIURA A,et al.P0370 relationship between attenuation of C3 glomerular deposition and clinical prognosis in IgA nephropathy:Repeat-biopsy based observation[J].Nephrol Dial Transplant,2020,35(Supplement_3):675. [13] 田秀娟,黄晨.IgA肾病免疫炎症发病机制研究进展[J].中华肾脏病杂志,2020,36(5):400-405. [14] FLOEGE J,MOURA IC,DAHA MR.New insights into the pathogenesis of IgA nephropathy[J].Semin Immunopathol,2014,36(4):431-442. [15] 许日聪,曹陶,徐艺,等.IgA肾病肾小球节段性硬化或粘连和肾功能下降的相关性分析[J].中华肾脏病杂志,2020,36(11):851-857. [16] COOK H T.Focal segmental glomerulosclerosis in IgA nephropathy:A result of primary podocyte injury?[J].Kidney Int,2011,79(6):581-583. [17] KIKUCHI K,SAIGUSA D,KANEMITSU Y,et al.Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease[J].Nat Commun ,2019,10(1):1835. [18] GANJALI S,GOTTO AM,RUSCICA M,et al.Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases[J].J Cell Physiol,2018,233(12):9237-9246. [19] FONSECA F,BALLERINI A P,IZAR M C,et al.Advanced chronic kidney disease is associated with higher serum concentration of monocyte microparticles[J].Life Sci,2020(260):118295. [20] KORAISHY F M,BOWE B,XIE Y,et al.Monocyte count modifies the association between chronic kidney disease and risk of death[J].Clin Nephrol,2018,90(3):194-208. [21] 王娇,汪丽珍,王昱,等.基于无创指标的IgA肾病诊断预测模型的建立与验证[J].中国临床医学,2022,29(4):603-609. [22] 王冲,王贵松,李月红.异常高密度脂蛋白在慢性肾脏病中的研究进展[J].中华肾脏病杂志,2019,35(4):316-320. [23] KIM H J,MORADI H,YUAN J,et al.Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney[J].Am J Physiol Renal Physiol,2009,296(6):F1297-F1306. [24] 马妍,谢红浪.载脂蛋白E相关肾小球疾病的诊治进展[J].肾脏病与透析肾移植杂志,2021,30(5):470-475. [25] 吴美豪,曹慧霞,王丽姣,等.单核细胞/高密度脂蛋白比值与慢性肾脏病疾病严重程度及预后的关系[J].中华肾脏病杂志,2021,37(7):567-575. [26] 梁晓玲,张春山,江琛.单核细胞与高密度脂蛋白胆固醇比值是慢性肾衰竭血液透析患者2年内死亡的独立影响因素[J].内科急危重症杂志,2023,29(2):141-145. |